So they are using a stronger dose (500mg2 per day) of CBD as an add-on with conventional antipsychotics than used in the monotherapy (the treatment of a disease with a single drug) trial from germany (200mg3 per day).
This means they may also have tolerability issues in this trial, because they are using larger doses than perhaps necessary. If it is as effective as an antipsychotic in monotherapy at 600mgās per day, 1000mgās per day in adjacent with a conventional antipsychotic might be overkill, donāt you think?
1 Like
It would be interesting to know the dose they used in the trial they had tolerability issues with. But currently I am out of steam!
I donāt know how these things work, thereās obviously a point where they figure out the therapeutic dosage, but maybe in phase 2, they use extra as theyāre only interested in results. But that does contradict the fact that they were dissapointed and their stock price took a hit in the phase 2 trial for the physical condition. Maybe it was more to do with lack of results than tolerability though.
Iām no longer getting my hopes up too high though. 2017 is a long way off as well.
The thing thatās dissapointing about all this comes back to what you said about the fact the trial isnāt using it as monotherapy.
Yeah, but this means we could perhaps lower our primarily medications down to a minimal level if we used CBD as an add-on. So assuming it does the job, I bet we can still manipulate the system to get what we want.
Hopefully. Itās at least a glimmer of hope.
If all goes well, this will come out in 2017, as will Encenicline. 2017 looks like a potentially very exciting year for us.
2 Likes
And in Cali, where I am from, pot will very likely become legal for recreational use in 2017 as well.
Avoid it. THC causes big problems.
2 Likes
I will be able to try strains high in CBD and virtually no THC without a prescription. So even if this trial doesnāt pull through, I will still be able to get my CBD to try.
1 Like
Good news. Read quoted material. This is from SciELO - Brasil - Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Theoretically this means the 1000mg per day dosage might not have tolerability issues after all. Hopefully there is a positive outcome, but will we see the true potential of CBD when combined with a conventional antipsychotic? Its effects might be the most apparent when used in monotherapy instead of as an add-on.
Now that they have more of a gauge of tolerability when it comes to CBD through trial and error, this information can now be applied to all future studies on CBD so the mistake isnāt made again of using too high of a dose. Iām sure they will apply this information to their trial on the effects of CBD as an add-on to antipsychotic medication. These people arenāt stupid. Theyāre just pissed the potency of dose can only go so far. Since CBD is a natural compound, CBD is CBD in just the same way h2o is h2o. There wonāt be variants of it like conventional antipsychotics when it comes to Abilify, Risperdal, and Geodon. The only thing they can change in it is its dose, unless they create synthetic forms of it, but according to my understanding, synthetic forms of pot can be very dangerous.
I stand corrected. Pot is likely to become legal in CA in 2016. Looks like I will be smoking Charlotteās web sooner than expected.
No studies yet.
ā[Inclusion Criteria) Patient is diagnosed with schizophrenia or a related psychotic disorder (such as schizoaffective or schizophreniform disorder) as defined by the Diagnostic and Statistical Manual of Mental Disorders Version 4.ā https://clinicaltrials.gov/ct2/show/NCT02006628
1 Like
So it sounds like they think it will help people with schizoaffective disorder too.
Hereās a CBD drug in phase 1 thatās being tested on its own from what I can see (not as an addon)
http://www.echo-pharma.com/en/products-and-pipeline/pipeline/schizophrenia/
Hereās another study being done in phase 2 using CBD in monotherapy: https://clinicaltrials.gov/ct2/show/NCT02088060
1 Like
Itās just a study though, it wonāt lead directly to an end product. Itās being conducted by Denmark mental health services.